Share

Chi-Med to start marketing new oncology drug in China by the end of January: CEO

Christian Hogg of Chi-Med outlines the company's future in China and the U.S. after China granted approval for use of surufatinib, its latest oncology drug.
02:46
Mon, Jan 4 20213:25 AM EST